Biohaven Ltd.
Biohaven Ltd. is a global clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for patients with debilitating neurological and rare diseases. Formed following the acquisition of Biohaven Pharmaceutical Holding Company Ltd. by Pfizer, Biohaven Ltd. retained the non-CGRP assets and is focused on advancing a diverse pipeline of promising drug candidates.
About Us
- Biohaven Ltd. - is committed to pioneering new treatments that address significant unmet medical needs in neuroscience and rare disorders. - The company leverages a deep understanding of disease biology and a patient-centric approach to accelerate the development of novel therapeutic options. - Its portfolio includes multiple clinical-stage programs aimed at transforming patient lives by providing innovative solutions for challenging conditions.
Vision
To be a leading biopharmaceutical company recognized for its innovative therapies that significantly improve the lives of patients globally, setting new standards in neuroscience and rare disease treatment.
Mission
To bring transformative new medicines to patients suffering from neurological and rare diseases with high unmet medical need, improving their lives and health outcomes.
Culture
- Biohaven Ltd. - fosters a culture driven by scientific excellence, innovation, collaboration, and a profound commitment to patients. - The company cultivates an agile and entrepreneurial environment that encourages rigorous research, rapid development, and ethical practices, prioritizing discovery and a patient-first mindset.
Specialties & Industries
Open Positions
No open positions at the moment
Check back later for new opportunities